Objectives: This study aimed to examine the long-term clinical outcomes of children with severe constipation, as defined by need for rectal biopsy (RB), and to determine which baseline characteristics were predictors of successful outcome. Methods: Children with severe constipation who underwent RB for evaluation of Hirschsprung disease at a tertiary medical center were eligible. A cohort of children with constipation without a history of RB served as controls (matched 2:1 by sex and age). Retrospective chart review of clinic visits was performed at baseline, 3, 6, 12, 18, and 24 months. Successful clinical outcomes were defined as !3 bowel movements weekly for !4 weeks, with 2 fecal incontinence episodes monthly, irrespective of laxative use. Results: A total of 175 RB children (90 boys, mean age: 6.7 years) were matched to 350 controls. Mean duration of constipation symptoms before intake in the RB group was significantly longer compared with controls (3.7 vs 0.4 years, P < 0.001). By 24 months, the cumulative percentage of children achieving at least 1 period of successful outcome was significantly higher in the control group compared with RB population (73% vs 24%, P < 0.001). Multivariate analysis revealed that younger age (P ¼ 0.001, odds ratio 0.87) and shorter duration of constipation before RB (P ¼ 0.03, odds ratio 0.45) were significant predictors of successful outcome. Conclusions: Only one-quarter of patients with severe constipation achieved successful outcome during 2-year follow-up. Younger age and shorter duration of constipation at time of biopsy were predictors of successful outcomes, emphasizing the importance of early diagnosis and initiation of treatment in this population.
gastroenterologist. The prevalence of constipation is estimated to be 0.7% to 29.6% across the world (1) . From 1992 to 2004, the rate of constipation diagnoses doubled and the rate of hospitalization increased 4-fold (2) . As of 2004, 5.4 million prescriptions were filled for constipation in the United States (2) . Historically, constipation has been perceived to be a symptom that children will outgrow as they age, but increasing evidence suggests that for a significant proportion of children with constipation, it remains a long-term problem, even lasting into adulthood (3, 4) .
Many pediatric cases of constipation are caused by slow transit constipation or pelvic outlet obstruction, the latter seen with functional fecal retention, anal sphincter hypertonicity and/or abnormal relaxation, and the sphincter abnormalities related to Hirschsprung disease (HD) (5) . Within this general population is a subset of patients with severe constipation whose disease burden is underappreciated as knowledge about the etiology, pathophysiology, and prognosis of severe constipation remains limited. With the rate of constipation diagnoses on the rise, practitioners will likely see more patients with severe constipation, highlighting the importance of further understanding of the disease.
Defining ''severe'' constipation however, can be difficult. We propose that a distinguishing marker of severe constipation is the need to evaluate for HD with a rectal suction biopsy (RB). Most commonly diagnosed in infants <1 year of age, HD is characterized by the absence of ganglion cells in the distal intestine. The diagnosis is made by RB wherein the presence of ganglion cells rules out HD (6, 7) . At our institution, the decision to perform an RB to evaluate for HD in a patient with constipation is based on the following features: poor response to laxative management, early age of onset,
What Is Known
Severe constipation is an increasingly common disorder in pediatrics. The care for these patients can be extremely time consuming and resource taxing. There is, however, limited evidence regarding the long-term outcomes of this population.
What Is New
For children with severe constipation as evidenced by need for rectal biopsy for Hirschsprung disease, significantly fewer achieved successful outcome compared with patients with moderate constipation. Younger age and shorter duration of constipation at biopsy was associated with successful outcomes. Earlier and more aggressive therapy may be warranted in these patients.
intractability of symptoms, absence of rectoanal inhibitory reflex on anorectal manometry, and/or findings on barium enema suggestive of HD. Therefore, the decision to obtain an RB for HD can be viewed as a surrogate for severe constipation.
Those patients with normal biopsies are diagnosed as having functional constipation, based on clinical history and Rome III criteria (8) . There is, however, a large range of symptom severity within the framework of a diagnosis of chronic functional constipation (9) . Given the scarcity of data, we aim to present the longterm follow-up of severely constipated patients undergoing RB, but not found to have HD. We compare the outcomes with a control population consisting of patients with mild to moderate constipation who did not require an RB. We also aim to examine which baseline characteristics were independent predictors of achieving successful outcomes.
METHODS
Pediatric patients (<21 years) who underwent RB for evaluation of HD secondary to severe constipation or concerning gastrointestinal (GI) symptoms at Massachusetts General Hospital (a tertiary medical center) between January 2001 and December 2010 were eligible. To be included as a case, an eligible patient must have obtained an RB and had a follow-up appointment with a pediatric gastroenterologist. Control subjects included those with International Classification of Diseases code 564.00 (constipation) who did not undergo RB and were evaluated in the same pediatric gastroenterology clinic during the same time period. Controls were matched for age (AE3 months) and sex in a 2:1 ratio to cases. This research protocol was approved by the institutional review board.
Retrospective chart review of GI clinic visits was performed by one investigator (K.T.) at baseline and at 3, 6, 12, 18, and 24 months after biopsy for patients who have undergone RB or after initial intake visit for controls. Data concerning laxative use, defecation frequency, abdominal pain, stool consistency, painful defecation, relapses, and fecal incontinence were documented at each visit and obtained via chart review.
Definition of Clinical Outcome
Encopresis was defined as the voluntary or involuntary passage of a normal bowel movement or loose stool in the underwear after toilet training (10) . We used previously reported definitions for our clinical outcome measures (3, 4, 11) . Successful outcome was defined as a period of at least 4 weeks with >3 bowel movements per week, without pain during defecation, and with <2 episodes of encopresis per month. Patients meeting these criteria at a given follow-up visit without the assistance of laxatives during the preceding 4 weeks were labeled as ''full responders.'' Patients meeting these criteria with the assistance of laxatives during the preceding 4 weeks qualified as ''partial responders'' and patients failing to meet criteria for success while on or off laxatives were considered to be ''nonresponders.'' A child was considered to have a relapse if the stooling frequency was <3 times per week, and/or encopresis occurred 2 or more times for a month after achieving an initial good clinical outcome.
Statistical Analysis
Baseline characteristics of the case and control cohorts were compared using x 2 and Student t tests. Univariate and multivariate logistic regression was used to examine the relation between predefined baseline characteristics and the probability of achieving a successful outcome (full responders) or any level of success (full and partial responders) at 1-and 2-year follow-up. The following baseline factors were examined: sex, age, duration of symptoms before RB or intake, soiling, abdominal pain, family history of constipation or irritable bowel syndrome, and personal history of milk intolerance or failure to thrive. The probability of achieving a successful outcome at different follow-up periods was analyzed assuming Weibull-distributed times and interval censoring between visits. The cumulative event distribution was estimated by KaplanMeier product-limit estimates assuming only right censoring.
RESULTS

Baseline Characteristics
Between 2001 and 2010, 264 patients underwent RB for HD at a tertiary medical center. Of these, 21 patients (7.9%) were diagnosed as having HD (median age: 3.4 days). A total of 68 patients with normal RB were lost to follow-up, of which 62 were neonates who had an RB performed within the first week of life. The 175 patients with RB (54% boys) who had follow-up with a pediatric gastroenterologist after biopsy constituted the study cohort. Using the International Classification of Diseases code 564.00 during the same time period, 6783 patients with mild or moderate constipation not severe enough to warrant RB were identified, of whom 350 subjects (2:1, randomized and age-and sex-matched to RB cohort) were identified and served as controls for the same interval.
The mean age at intake for patients with RB was 6.7 years, with a range from 1 month to 20 years. The duration of constipation symptoms before intake was a mean of 3.7 years, which was significantly longer than for controls (0.4 years, P < 0.001). Compared with controls, patients with RB had significantly higher baseline rates of stool incontinence (P < 0.001), hard stools (P < 0.016), straining with defecation (P < 0.001), and abdominal pain (P < 0.001). There was no significant difference in baseline characteristics between boys and girls in our RB study population. Analyzing by age however, in patients 13 years or older, there was a greater prevalence of girls (67%, n ¼ 24). Baseline characteristics are presented in Table 1 .
For the RB population, 120 patients (68.6%) maintained follow-up through 24 months, compared with 131 (37.4%) subjects in the control group. Thirty-two percent of patients with RB required the use of 2 or more laxatives at 3 months compared with 25.2% for controls; at 24 months, laxative usage rates were significantly greater among patients with RB (59.2% vs 6.1% in controls, P < 0.001). Laxatives used by patients varied widely, including lactulose, polyethylene glycol-3350, senna, bisacodyl, docusate, enemas, lubiprostone, and magnesium products. No patients in cohort were treated with antegrade enemas or surgery.
Clinical Outcome During Follow-up
At 3 months, 14.5% of patients with RB achieved success without using laxatives (full responders), whereas 44.2% of patients met the criteria for success but still required the use of laxatives (partial responders), leaving the remaining 41.3% of patients unable to achieve success (nonresponders) (Fig. 1B) . Comparatively, 16.8%, 48.7%, and 34.5% of control subjects achieved full response, partial response, or no response, respectively, at 3 months (Fig. 1A) . By 24 months, a significant difference between groups was observed with 5.0% of patients with RB having full response, 54.2% with partial response, and 40.8% nonresponders. In contrast, 70.2%, 25.2%, and 4.6% of controls were full, partial, and nonresponders, respectively. Significantly more patients were able to achieve full response at 24 months in the control group compared with RB patients (P < 0.001). Also at 24 months, the loss to follow-up rate was 31.4% for patients with RB compared with 62.6% for the control group.
As the majority of HD is diagnosed within the first year of life, the threshold to obtain an RB for HD is often lower for these younger patients. Removing infants <1 year of age (n ¼ 39) from analysis yielded the following results: at 3-month follow-up, 3.7%, 46.3%, and 50.0% of RB subjects achieved full, partial, and no response, respectively. By 24 months, the ratios remained similar at 2.7%, 54.5%, and 42.9%, respectively. Removing infants did not change conclusions in comparing RB and control patients. In particular, patients with RB of 1 year and older were significantly less likely to achieve full responder status at 24 months' follow-up compared with controls (2.7% vs 70.2%, P < 0.001).
The cumulative percentage of children achieving at least 1 period of successful outcome by 24 months' follow-up was significantly greater in the control group than our RB population (73% vs 24%, P < 0.001). The probability of success for both control and RB groups was similar through 12 months' follow-up, after which time the proportion of controls achieving success continued to rise while few additional patients with RB achieved success (Fig. 2) .
Prognostic Factors for Success
Multivariate logistic regression was used to examine baseline characteristics as independent predictors of successful outcome without laxatives (full responders) ( Table 2) . At 12 months, those at a younger age (P ¼ 0.02, odds ratio [OR] 0.94) at the time of biopsy were significantly more likely to achieve success. Duration of constipation symptoms before timing of RB was also significant (P ¼ 0.04, OR 0.68) as those patients with shorter duration were more likely to achieve success. Other factors significantly associated with success included a lack of soiling (P < 0.001, OR 0.31) and a lack of abdominal discomfort (P ¼ 0.01, OR 0.59). Patients without a family history of irritable bowel syndrome were significantly (P ¼ 0.007, OR 0.28) more likely to achieve success at the 1 year follow-up visit. Looking at these same factors at the 24 months' visit, younger age at RB (P ¼ 0.001, OR 0.87) and shorter duration of constipation before RB (P ¼ 0.03, OR 0.45) were significant in predicting ability to achieve success. Examining baseline factors that predict likely failure at 24 months, soiling is a significant factor (P ¼ 0.01, OR 2.54).
After achievement of full clinical response, relapse rates within the RB group rose steadily at each interval visit, with 36% of patients having at least 1 relapse event during the 2-year follow-up interval. There was a slight male predominance with 34% of boys experiencing a relapse and 28% of girls. Six percent of all patients never achieved any level of success and thus were unable to be evaluated for relapse. For the control population, 33% experienced a relapse during follow-up. The sex breakdown was similar to the patients with RB with 40% of boys and 25% of girls experiencing relapse.
DISCUSSION
This retrospective, long-term follow-up study of children with severe constipation revealed that at 2-year follow-up, a striking number (76%) of children were unable to achieve success without Time of follow-up (months) 18 24 A B the use of laxatives at any point during the study. In comparison, the control group with mild to moderate constipation had a much lower rate of failure with only 27% unable to achieve success. Poor clinical outcomes were associated with older age, longer duration of constipation at time of presentation, and soiling. For patients with RB who achieved full response, most did so by the 6-month mark, as there were almost no patients seen at subsequent follow-up visits who were able to achieve full response. In contrast, the probability of complete response increased steadily among controls with time. These findings suggest that for this population of mild to moderate constipation, laxatives may be needed initially, but ultimately there is a high likelihood of achieving normal defecation with time.
Significantly more patients were able to achieve full response to treatment at 24 months in the control group compared with patients with RB (P < 0.001). In fact, the values seen at 24 months likely underestimate the true number of patients who achieved success without laxatives as 1 possible explanation is that those patients are more likely to be lost to follow-up. For the RB group, there were fewer patients lost to follow-up compared with the control group, likely because ongoing constipation issues required ongoing specialist visits.
The contrast in outcomes between RB and control groups highlights the underlying difficulty in treating severe constipation. Although treatment was not standardized, the use of laxatives was typical, often consisting of an osmotic agent such as polyethylene glycol-3350 and/or a stimulant such as bisacodyl. With 40% nonimprovement, laxative therapy alone was ineffectual in treating many patients with RB and suggests that treatment plans for patients with severe constipation need to be broadened and include multidisciplinary providers. Psychiatric or behavioral interventions may be needed as well (12, 13) . Pelvic floor dysfunction may also be a factor and additional testing by anorectal manometry can be beneficial to identify appropriate patients who may benefit from biofeedback and pelvic floor physical therapy (14, 15) . Colonic manometry can assist in identifying colonic dysmotility and guiding other treatment options (16) (17) (18) . Novel drug therapies will also likely play a role in treatment. Prucalopride, a highly selective 5-HT4 receptor agonist, improved bowel function by 69% in adults with severe chronic constipation (19) and a phase 3 clinical trial is underway in pediatric patients with functional constipation. Similar studies are underway for other agents such as linaclotide and lubiprostone.
We notably ran an analysis eliminating infants <1 year from the RB group. As infants often get an RB for reasons other than constipation in this age group, removing them reduced confounders and further allowed us to assess the population of interest-namely outcomes in severely constipated patients. Interestingly, by the end of 24 months, the outcome percentages look similar if one includes infants in the analysis. This likely reflects a high lost to follow-up rate (82%) in these infants by 24 months. We suspect that the majority of these patients had symptom improvement and left the pediatric gastroenterology office. Indeed, 75% had achieved full response status at their last follow-up appointment.
For our RB population of severe constipation, our study showed that those who were younger or had shorter duration of constipation at time of biopsy had higher odds of success by 24 months. With regard to the younger age factor, this may partly reflect the fact that gastroenterologists have a higher suspicion for HD in younger children, particularly those in the neonatal period and under the age of 1 year, and thus have a lower threshold of disease severity for obtaining an RB. These findings may also suggest that earlier recognition of constipation by parents and pediatricians and prompt involvement of a pediatric gastroenterologist can lead to improved outcomes.
Despite the fact that patients in our RB population had significantly higher baseline rates of soiling, hard stools, straining with defecation, and abdominal pain compared with controls, none of these were significant in predicting successful outcome by multivariate analysis. Although frequently queried by physicians at visits, these factors seem to be better suited to monitoring progress as opposed to key indicators of disease severity. Interestingly, a history of soiling was significantly associated with failure and nonresponse, which is not surprising given the difficulty of treating encopresis.
We also noted a higher overall prevalence of males (54%) with severe constipation compared with girls (46%), which mirrors the prevalence of constipation in other studies, although this was not statistically significant (3, 4) . We noted that in patients older than 13 years, there was a greater prevalence of girls (67%) with severe constipation. This finding has been noted in previous studies (11) , although the reasons are unclear. One possibility is that teenage girls are at higher risk than boys for depression and anxiety (20) , which are associated risk factors in the development of constipation (21, 22) . The observed female predominance in our teenage patients mirrors the higher incidence of functional GI disorders in adolescent (23) and adult girls as well (24, 25) .
Although our review does not examine the reasoning behind why a physician ordered the RB to look for HD, common indications include delayed BM in neonate, absent/incomplete rectoanal inhibitory reflex on anorectal manometry, abnormal barium enema findings, or clinical suspicion. This study's findings of poor outcomes in RB patients suggests that those patients who undergo RB and are found not to have HD, may in fact represent a distinct physiologic subset of children who go onto have a poor clinical course of constipation and warrant aggressive multidisciplinary treatment.
We acknowledge several limitations. Our study is observational and therefore we cannot exclude the possibility that unmeasured confounders may explain our observed observations. Furthermore, treatment plans were not standardized. Although the variety in treatment plans reflects the reality of a large clinical practice, a long-term prospective trial with standardized treatment could better address this limitation. Additional concern could be raised about the potential for selection bias as patients with RB had longer duration of constipation at intake and were older compared with controls. Also, because of the transition from paper to electronic medical records at our institution during the study period, anorectal manometry data were noted to be incomplete which limited its role in our analysis. Our aim was, however, to evaluate the fundamental characteristics that distinguish severe constipation from more moderate constipation, which includes these key differentiating characteristics. We also adjusted various baseline characteristics in a multivariate logistic regression model. Finally, subjects were lost to follow-up in both the RB and control groups. We suspect that a significant number of those patients were those who improved and were ''graduated'' from the gastroenterologist's office, although we cannot say this with certainty. We suspect that this scenario occurs more frequently in the control group of mild-to-moderate constipation patients as opposed to the RB group. That said, our use of survival analysis accounts for loss to follow-up (censoring) and yields conservative estimates of difference between RB and control patients if loss to follow-up is associated with a favorable outcome. In addition, our study was performed at a single tertiary center, which may limit generalizability. Nevertheless, the center's pediatric patients come from a large pediatric primary care referral base suggesting broader applicability of the findings.
Although a retrospective study, this is one of the first to evaluate the long-term outcomes in the challenging population of severe, chronically constipated children. Results of the study warrant confirmation and further investigation with a prospective study design.
CONCLUSIONS
For those patients with mild-to-moderate constipation, nearly three-quarters of patients are able to meet the criteria for success by 2-year follow-up. This finding is in sharp contrast to patients who warrant an RB for HD who have severe constipation, where only one-quarter is able to achieve successful outcome over the same interval. This suggests that for this population, a significant number of patients experience constipation for prolonged periods requiring aggressive treatment and long-term follow-up. Younger age at biopsy and shorter duration of constipation before biopsy yielded greater chance at achieving successful resolution of constipation without laxatives, emphasizing the importance of early diagnosis and initiation of multidisciplinary treatment and aggressive constipation management program.
